Today Stories

Agreement to leverage dedicated commercial fill-finish manufacturing capacity in the US for mRNA vaccines and therapies CAMBRIDGE, Mass., and WALTHAM, Mass., February 23, 2022 – Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced a 15-year strategic collaboration agreement to enable dedicated large-scale manufacturing in the U.S. of Spikevax®, Moderna’s COVID-19 vaccine, and other investigational mRNA medicines in its pipeline. “Thermo Fisher continues to be a trusted partner, bringing a full range of products and services that have enabled us to deliver innovative medicines at an unprecedented speed and scale,” said Jua…

Haleon will be a new world-leader in consumer health with an exceptional portfolio of category-leading brands, including Sensodyne, Voltaren, Panadol and Centrum Business is on track to demerge and list as a new company in mid-2022 GlaxoSmithKline plc (GSK) today announced that the new company, to result from the proposed demerger of Consumer Healthcare from GSK in mid-2022, will be called Haleon. Haleon (pronounced "Hay-Lee-On") is inspired by the merging of the words 'Hale', which is an old English word that means 'in good health' and Leon, which is associated with the word 'strength'. The new brand identity was developed with input from employees, healthcare practitioners and consumers and will be deployed in more than 100 markets around the world where the business operates. The crea…

Today is World Encephalitis Day – the global awareness day for people who have been directly or indirectly affected by encephalitis. Founded by The Encephalitis Society in 2014, it has reached over 236 million people through media features, events and social media. Take a look at World Encephalitis Day through the years. What is Encephalitis? Encephalitis is inflammation of the brain and is caused by an infection, or by the immune system attacking the brain. Anyone can be affected by encephalitis, regardless of age, gender, and ethnicity. It has a high death rate, and survivors are often left with brain injuries with life-changing consequences. View more encephalitis facts and figures. How Can You Get Involved? There are three main ways to get involved this World Encephalitis Day: Go #Red…

- New expanded indication provides patients suffering from earlier stages of heart failure access to the CardioMEMS™ HF System, a small implantable sensor that can flag early warning signs of worsening heart failure - FDA approval was supported by data from the GUIDE-HF trial, which suggested that the CardioMEMS sensor can reduce hospitalizations and improve care for more types of patients living with heart failure ABBOTT PARK, Ill., Feb. 21, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for the company's CardioMEMS™ HF System to support the care of more people living with heart failure. With the expanded indication, an additional 1.2 million U.S. patients1 are now eligible to benefit from advan…

Lilly, Breastcancer.org, For the Breast of Us, Living Beyond Breast Cancer, and Susan G. Komen join together for new education initiative to support people with early breast cancer at high risk for recurrence INDIANAPOLIS, Feb. 16, 2022 /PRNewswire/ -- Breast cancer is a complex disease with many factors that influence whether the cancer will return or spread, yet few resources exist to help people diagnosed with breast cancer understand these risk factors. In recognizing the need for more education about breast cancer recurrence, Eli Lilly and Company (NYSE: LLY) today launched a new education campaign in collaboration with Breastcancer.org, For the Breast of Us, Living Beyond Breast Cancer, and Susan G. Komen. This campaign aims to educate, support, connect, and empower people diagnosed…

Long-term agreement includes a series of investments to acquire new equipment and adapt the present ROVI drug product fill-finish facilities and production lines in Spain CAMBRIDGE, MA and MADRID, SPAIN / ACCESSWIRE / February 16, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Laboratorios Farmacéuticos Rovi, S.A. (BME: ROVI), a pan-European pharmaceutical company specializing and engaging in the research, development, contract manufacturing and marketing of small molecules and biological specialties, today announced a long-term collaboration to increase capacities for the compounding, aseptic filling, inspection, labeling, and packaging of ROVI's facilities, located in Madrid, San Sebastián de los Reyes and Alcalá…

Heidelberg Pharma Announces First Patient Dosed with Antibody Targeted Amanitin Conjugate HDP-101 in Multiple Myeloma Ladenburg, Germany, 15 February 2022 - Heidelberg Pharma AG (FSE: HPHA) today announced that the first patient has been dosed with HDP-101 in a Phase I/IIa study at the Winship Cancer Institute of Emory University, Atlanta, GA, USA. The open-label, multi-center Phase I/IIa study will evaluate HDP-101, a BCMA antibody-Amanitin conjugate, for the treatment of relapsed or refractory multiple myeloma, a bone marrow cancer with high unmet medical need. Dr. András Strassz, Chief Medical Officer of Heidelberg Pharma, commented: "It is an important step for Heidelberg Pharma to have the first patient dosed in our study. This Phase I/IIa study will test a new mode of action in oncol…

PARIS--(BUSINESS WIRE)--On the occasion of World Epilepsy Day (14th of February 2022), Angelini Pharma, international Italian pharmaceutical company, is committed to provide patients and healthcare professionals with innovative solutions improving the care of patients with epilepsy. Epilepsy is a common neurological disorder that typically results in seizures of various types, with focal seizures being the most common.1 The essential treatment goal of epilepsy therapy is freedom from seizures.2 The global disease burden of epilepsy is high.3,4 A diagnosis of epilepsy confers significant disability on the individual, including physical, psychological, and social issues that negatively impact self-esteem, family environment, relationships, leisure and working life.3,5 Long-term outcomes for…

The Cell and Gene Therapy Catapult has partnered with MICA Biosystems to begin the journey of bringing their revolutionary regenerative medicine technology to the MHRA. London 10th February 2022: The Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in the advancement of cell and gene therapies, announces a collaboration with MICA Biosystems (MICA), a Birmingham based medical technology company, to leverage the expertise of the CGT Catapult in taking novel technologies and concepts through to clinical trials. MICA have developed a ground-breaking platform that uses patented nanotechnology to control a patient’s stem cells, in situ, to repair or replace damaged or diseased tissue. The first application of MICA’s technology is i…

Arrangement Includes Labcorp’s Acquisition of Certain Outreach Laboratory Assets Strategic Collaboration Expands Patient Access to Labcorp’s Services, Drives Efficiencies and Advances Clinical Innovation BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has entered into agreements to create a comprehensive strategic relationship with Ascension, one of the nation’s leading Catholic and non-profit health systems. Through the expansive strategic collaboration, Labcorp will manage Ascension’s hospital-based laboratories in 10 states and purchase select assets of the health system’s outreach laboratory business. This long-term relationship will expand Labcorp’s clinical laboratory services in several states across the countr…

Paris, February 8, 2022. Sanofi announced today the completion of its acquisition of Amunix Pharmaceuticals, Inc, adding a promising pipeline of T-cell engagers and cytokine therapies. The acquisition also provides access to Amunix Pro-XTEN, XPAT, and XPAC technology to deliver next generation Conditionally Activated Biologics. The technology platform is highly complementary to Sanofi’s existing R&D platforms and supports Sanofi’s efforts to accelerate and expand its contributions to innovative medicines for oncology patients, with approximately 20 molecules currently in development. Weil, Gotshal & Manges LLP is acting as Sanofi’s legal counsel. Centerview Partners LLC is acting as financial advisor to Amunix and Fenwick & West LLP is acting as its legal counsel. About SanofiW…

Agreement brings complementary capabilities in clinical, regulatory and scientific affairs for clients in key markets Frankfurt, Germany – 8 January 2022: PharmaLex Group, a leading provider of specialized services for the pharma, biotech and medtech industries worldwide, has announced a merger agreement with Ascent Development Services, a Japan-based leader in enabling the integration of  Asia into global pharmaceutical product development. Founded in 2017, Ascent’s team of experts work with emerging biopharma companies to understand and overcome differences in medical practice, culture and language in order to achieve the optimal strategic and operational integration of Asia into global drug development.  Headquartered in Tokyo, Ascent employs staff across Asia, including China, Korea, M…

Ortenberg, 7th February 2022. BMG LABTECH introduced the new VANTAstarTM microplate reader, further expanding its range of high-quality, made-in-Germany instruments. The latest addition to the BMG LABTECH portfolio, the VANTAstar was conceived for ease-of-use and flexibility for a wide range of applications in basic research and life sciences. The VANTAstar was officially introduced to public at the SLAS 2022 conference and exhibition in Boston, USA. Flexible microplate reader with simplified workflows The VANTAstar is a compact multi-mode microplate reader and is equipped with three features that enable an effortless detection setup and improve data quality: Enhanced Dynamic Range (EDR) technology, a rapid full-plate auto-focus and automatic luminescence cross-talk reduction. The EDR tech…

To mark World Cancer Day on 4th February, EIT Health vows to back innovative technologies to support early screening and cancer diagnosis EIT Health says that earlier diagnosis will save money on treatment – allowing for savings that can be reinvested into better services Without concerted action, cancer cases are expected to increase by 25 per cent by 2035 making it the leading cause of death in the EU[1] EIT Health, part of the European Institute of Innovation and Technology, today marks World Cancer Day by vowing to back more innovative technologies that can help to support early screening and diagnosis of cancer in a bid to ‘Close the Care Gap’ and help provide equitable care for all. This year’s World Cancer Day’s theme is all about raising awareness of the equity gap that affects…

As the COVID-19 pandemic continues to have a disproportionate impact on women, Organon issues a call to action for other leaders to create opportunities to focus on women’s health in the UK LONDON, UK — Organon (NYSE: OGN), a global women’s health company, is designating International Women’s Day (IWD) on 8th March as a day to recognise the growing health disparities that women face that have been exacerbated by the COVID-19 pandemic. Since its inception, IWD has focused on accelerating gender parity. Organon recognises the need for a global effort to address her health and understands that it needs to start with its own employees by giving them paid time off to attend to their own health needs. The company is also inviting organisations in the UK and across the globe to join in raising aw…

Nina Capital, APEX Medical and Cambridge Enterprise invest in transformational open-source data technology – to deliver precision medicine at scale   LONDON, UK. February 1, 2022:  University of Cambridge technology spin-out Zetta Genomics announces that is has raised £2.5 million in new seed funding. The successful round secures leading global Venture Capital (VC) investment in the company’s XetaBase platform – a transformational genomic data management technology that powers the discovery and delivery of precision medicine at scale.   Data for the precision medicine era  Built on the open-source OpenCB platform, co-developed by Zetta Genomics founder, Ignacio Medina, XetaBase allows researchers and clinicians to securely store, easily access and dynamically interrogate vast and increasin…

Vabysmo (faricimab-svoa) targets and inhibits two disease pathways that drive neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME) Vabysmo is the only injectable eye medicine approved simultaneously in the US for nAMD and DME, with flexible dosing regimens based on patient need Basel, 31 January 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Vabysmo™ (faricimab-svoa) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). Neovascular AMD and DME are two leading causes of vision loss worldwide.1 Vabysmo targets and inhibits two disease pathways linked to a number of vision-threatening retinal conditions by neutralisin…

Parenteral and device manufacturing site will increase the number of people around the world who may benefit from Lilly's medicines INDIANAPOLIS, Jan. 28, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) plans to invest over $1 billion to create a new manufacturing site, along with nearly 600 new jobs in Concord, North Carolina. The brand-new facility will utilize the latest technology to manufacture parenteral (injectable) products and devices and increase the company's manufacturing capacity. "Lilly is entering an exciting period of growth and we are committed to delivering innovative medicines to patients around the world," said Edgardo Hernandez, senior vice president and president, Lilly Manufacturing Operations. "Expanding our manufacturing footprint in North Carolina enables…

Phase 1 trial aims to build on response seen in proof-of-concept trial CAMBRIDGE, MA and NEW YORK, NY / ACCESSWIRE / January 27, 2022 / IAVI, the nonprofit scientific research organization, and biotechnology company Moderna announced today that first doses have been administered in a clinical trial of experimental HIV vaccine antigens at George Washington University (GWU) School of Medicine and Health Sciences in Washington, D.C. The Phase 1 trial, IAVI G002, is designed to test the hypothesis that sequential administration of priming and boosting HIV immunogens delivered by messenger RNA (mRNA) can induce specific classes of B-cell responses and guide their early maturation toward broadly neutralizing antibody (bnAb) development. The induction of bnAbs is widely considered to be a goal of…

Cardiff, UK, January 24, 2022 - TrakCel, a leading supplier of cellular orchestration solutions for the cell and gene therapy industry, today announces it is launching a software integration resulting from a collaborative, non-exclusive partnership with Körber, the specialists for complete handling systems for pharmaceutical and medical products. The collaboration results in a working integration between OCELLOS by TrakCel and PAS-X from Körber. This will allow cell and gene therapy customers of both companies to effectively share data detailing manufacturing events, and milestones between the two systems such as starting checks, fill and finish and product release, whilst also providing full traceability and audit logs. TrakCel’s OCELLOS has ensured that developers and other cell and gene…